Atezolizumab for untreated advanced renal cell carcinoma [ID1365]
Discontinued
Reference number: GID-TA10338
As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of atezolizumab for untreated advanced renal cell carcinoma.
However, the company have advised NICE that based on the currently available data from the Phase III IMmotion151 trial, they will be withdrawing their application for regulatory approval from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its work programme.
As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes.